Jazz Pharmaceuticals Plc Stock News

Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults Accelerated approval based on an overall response rate in patients with progressive disease following prior therapy Company to host investor webcast on August 27, 2025 For U.S. media and investors only DUBLIN , Aug. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals ...

The U.S. Food and Drug Administration said on Wednesday that it has approved Jazz Pharmaceuticals' drug to treat diffuse midline glioma, a rare and aggressive tumor, in adults and children aged one year and older.

Jazz (JAZZ) Q2 Revenue Rises 2%

Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Bruce C. Cozadd - Co-Founder, Chairman & CEO Jack Spinks - Corporate Participant Philip L.

– Renee Gala named as President and CEO, effective August 11 – – Total revenues of $1.05 billion in 2Q25 – – Xywav ® revenues grew 13% year-over-year, with robust net patient adds of 625 quarter-over-quarter – – Zepzelca ® granted Priority Review in 1L ES-SCLC – DUBLIN , Aug. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter...

DUBLIN , July 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 second quarter financial results on Tuesday, August 5, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m.

– Selection Follows Robust Succession Process Led by the Board – – Bruce Cozadd to Retire as CEO and Remain Chairperson of the Board of Directors – DUBLIN , July 10, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Jazz Board of Directors has unanimously selected Renee Gala, Jazz's President and Chief Operating Officer, as the President and Chief Executive O...

Jazz Pharmaceuticals (NASDAQ: JAZZ) is currently trading at approximately $110, having decreased by 11% year-to-date, even after a significant positive development with the conditional European Commission Marketing Authorization for Ziihera (zanidatamab) aimed at advanced HER2-Positive Biliary Tract Cancer. Ziihera is the first HER2-targeted therapy approved in the EU for this condition, with a...